PreTarg-it® - Unlocking the Full Potential of Radioimmunotherapy
At OncoOne, we’re advancing cancer care with our innovative PreTarg-it® platform, which combines targeted antibodies and radiotherapy to treat challenging cancers more precisely while minimizing damage to healthy tissues.
How the PreTarg-it® Platform Works
Our approach is based on the principles of pretargeted radioimmunotherapy (PRIT), a sophisticated form of cancer treatment that separates the delivery of a tumor-targeting agent, such as a bispecific antibody from the delivery of a radioligand (radioactive payload). This two-component system enhances the targeting of cancer cells while minimizing the exposure of healthy tissues to radiation.
How the PreTarg-it® Platform Works
Our approach is based on the principles of pretargeted radioimmunotherapy (PRIT), a sophisticated form of cancer treatment that separates the delivery of a tumor-targeting agent, such as a bispecific antibody from the delivery of a radioligand (radioactive payload). This two-component system enhances the targeting of cancer cells while minimizing the exposure of healthy tissues to radiation.
From Targeting to Treatment: Three Steps to Defeat Cancer
Step 1: Bispecific Antibody Administration
Step 2: Tumor Accumulation and Clearance
Step 3: Radioactive Payload Administration
A bispecific antibody is administered to the patient. This antibody is designed to bind specifically to tumor antigens while carrying a secondary binding site for a radioligand.
The bispecific antibody accumulates in the tumor. During a short waiting period, any unbound antibodies clear from the bloodstream and other healthy tissues
The radioligand is administered and quickly enters the tumor and attaches to the antibodies already bound to the tumor, delivering targeted radiation directly to the cancer cells.
Maximized Efficacy:
Reduces radiation exposure to healthy tissues.
Our Focus on Research and Development
At OncoOne, we are advancing four key research programs under the PreTarg-it® platform aimed at developing therapeutic solutions for difficult-to-treat solid tumors such as those found in the pancreas, ovary, lung, and stomach.
Our programs focus on bispecific antibodies targeting specific tumor markers, including oxMIF, mesothelin (MSLN), folate receptor-α (FRα), and HER2.
